Home > Insider Trading > Filing (0001179110-13-011142)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1434868	Esperion Therapeutics Inc.	ESPR	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1172252	N Andrew Schiff	888 7Th Avenue 30Th Floor New York NY 10106	No	No	Yes	No
1250195	Steve Elms	888 7Th Avenue, 30Th Floor New York NY 10106	No	No	Yes	No
1297291	J Dennis Purcell	888 7Th Avenue, 30Th Floor New York NY 10106	No	No	Yes	No
1350778	Aisling Capital Ii Lp	888 7Th Avenue 30Th Floor New York NY 10106	No	No	Yes	No
1376171	Aisling Capital Partners Llc	888 7Th Avenue, 30Th Floor New York NY 10106	No	No	Yes	No
1376172	Aisling Capital Partners, Lp	888 7Th Avenue, 30Th Floor New York NY 10106	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-07-01	1,816,475	$0.00	1,816,475	No	4	C	Indirect	By Aisling Capital II, L.P.
Common Stock	Acquisiton	2013-07-01	238,119	$14.00	2,054,594	No	4	P	Indirect	By Aisling Capital II, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Aisling Capital II, L.P.
No	4	P	Indirect	By Aisling Capital II, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2013-07-01	1,816,475	$0.00	1,816,475	$0.00
Series A Preferred Stock	Warrant to Purchase Preferred Stock	Disposition	2013-07-01	497,666	$0.00	497,666	$1.00
Common Stock	Warrant to Purchase Common Stock	Acquisiton	2013-07-01	71,237	$0.00	71,237	$6.99

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Indirect
0	2018-02-12	No	4	J	Indirect
71,237	2018-02-12	No	4	J	Indirect

Footnotes

The Series A Preferred Stock was automatically converted into Common Stock on a 6.986-for-1 basis upon the closing of the Issuer's initial public offering without payment of further consideration and had no expiration date.
The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling Capital Partners, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling.
The warrant is immediately exercisable.
Upon the closing of the Issuer's initial public offering, this warrant to purchase shares of Series A Preferred Stock automatically converted on a 6.986-for-1 basis into a warrant to purchase shares of Common Stock, and the exercise price automatically adjusted accordingly. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrant and the change in exercise price.